AGL 40.22 Increased By ▲ 0.21 (0.52%)
AIRLINK 126.99 Decreased By ▼ -1.00 (-0.78%)
BOP 6.61 Increased By ▲ 0.01 (0.15%)
CNERGY 4.51 Decreased By ▼ -0.09 (-1.96%)
DCL 8.54 Increased By ▲ 0.06 (0.71%)
DFML 41.90 Increased By ▲ 0.42 (1.01%)
DGKC 87.25 Increased By ▲ 0.67 (0.77%)
FCCL 32.65 Increased By ▲ 0.51 (1.59%)
FFBL 65.35 Decreased By ▼ -0.07 (-0.11%)
FFL 10.25 No Change ▼ 0.00 (0%)
HUBC 109.79 Decreased By ▼ -0.70 (-0.63%)
HUMNL 14.55 Decreased By ▼ -0.20 (-1.36%)
KEL 5.12 Decreased By ▼ -0.01 (-0.19%)
KOSM 7.62 Increased By ▲ 0.50 (7.02%)
MLCF 41.65 No Change ▼ 0.00 (0%)
NBP 59.65 Decreased By ▼ -0.44 (-0.73%)
OGDC 194.40 Decreased By ▼ -0.29 (-0.15%)
PAEL 28.17 Increased By ▲ 0.22 (0.79%)
PIBTL 7.87 Decreased By ▼ -0.13 (-1.63%)
PPL 152.05 Increased By ▲ 0.88 (0.58%)
PRL 26.59 Decreased By ▼ -0.29 (-1.08%)
PTC 16.01 Increased By ▲ 0.01 (0.06%)
SEARL 82.50 Increased By ▲ 4.30 (5.5%)
TELE 7.48 Increased By ▲ 0.09 (1.22%)
TOMCL 35.45 Decreased By ▼ -0.22 (-0.62%)
TPLP 8.20 Increased By ▲ 0.29 (3.67%)
TREET 16.16 Increased By ▲ 0.27 (1.7%)
TRG 52.78 Increased By ▲ 0.02 (0.04%)
UNITY 26.50 Decreased By ▼ -0.05 (-0.19%)
WTL 1.26 Decreased By ▼ -0.01 (-0.79%)
BR100 9,918 Decreased By -2.1 (-0.02%)
BR30 30,797 Increased By 45.1 (0.15%)
KSE100 93,572 Increased By 347.3 (0.37%)
KSE30 28,992 Increased By 107.4 (0.37%)

NEW YORK: The US on Thursday authorized Merck & Co’s antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving the go-ahead to a similar but more effective treatment from Pfizer Inc. Merck’s drug, molnupiravir developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.

The U.S. Food and Drug Administration authorized Merck’s drug to treat mild-to-moderate COVID-19 in adults who are at risk for severe disease, and for whom alternative COVID-19 treatments are not accessible or clinically appropriate.

Pfizer’s drug, Paxlovid was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data.

The Pfizer treatment’s two-drug regimen may not be appropriate for some patients because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines.

Comments

Comments are closed.